Last reviewed · How we verify
PF-07220060 CDK4 inhibitor (pf-07220060-cdk4-inhibitor)
At a glance
| Generic name | pf-07220060-cdk4-inhibitor |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Dyspepsia
- Influenza like illness
- Headache
- Nasal congestion
- Oropharyngeal pain
- Dry skin
- Abdominal pain
- Application site irritation
- Pain in extremity
- Cough
- Skin irritation
Key clinical trials
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults (PHASE1)
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (PHASE3)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (PHASE2)
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (PHASE1)
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (PHASE2)
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (PHASE1)
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors (PHASE1)
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07220060 CDK4 inhibitor CI brief — competitive landscape report
- PF-07220060 CDK4 inhibitor updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI